首页 > 市场调查报告书 > 医疗设备

生技设备

市场调查报告书

商品编码

1811800

生物银行市场 - 全球和区域分析：按产品和服务、储存类型、样本类型、所有者、生物银行类型、应用、国家和地区进行分析和预测（2025-2035 年）

Biobanking Market - A Global and Regional Analysis: Focus on Product and Service, Storage Type, Sample Type, Ownership, Biobank Type, Application, Country, and Region - Analysis and Forecast, 2025-2035

出版日期: 2025年09月15日 | 出版商:

BIS Research | 英文 120 Pages | 商品交期: 1-5个工作天内

价格

简介目录图表

生物银行市场的主要成长要素之一是个人化医疗需求的不断增长。

随着基因组学和生物技术的进步，根据每位患者的基因资讯优化医疗保健的趋势日益增长。生物样本库保存多样化的生物样本，以了解基因变异及其对健康和疾病的影响，从而开发更有效、副作用更少的标靶治疗和治疗方法。

此外，癌症、糖尿病和心血管疾病等慢性疾病的增加也推动了对生物样本库的需求。提供生物材料库使研究人员能够识别疾病的生物标记物，了解疾病机制，并开发新的诊断和治疗方法。随着个人化医疗成为现代医学的核心支柱，对提供高品质生物样本的生物样本库的需求预计将持续成长。

儘管生物银行市场持续成长，但仍存在许多挑战。其中最主要的挑战之一是围绕着生物样本采集、储存和使用的伦理和法律问题。知情同意、隐私以及捐赠者资讯的保密性等问题仍然是主要挑战。尤其是在处理遗传资讯等敏感资料时，样本捐赠者提供知情同意并保护其隐私至关重要。

此外，不同地区和机构的生物银行法规和标准化缺乏统一性，导致资料品质、样本处理和储存方面存在差异。这种标准化的缺乏使研究机构之间的数据共用和协作变得复杂，限制了生物样本库资源的全球效用。

最后，维护生物库会带来财务和基础设施的挑战：长期管理大量资料和样本需要对储存设施等实体基础设施及其操作技术进行大量投资。

全球生物银行市场最重要的新兴趋势之一是数位技术与自动化的融合。伴随这一趋势的是先进数据管理系统、人工智慧驱动平台以及样本采集、储存和分析自动化的引入。这些技术使生物银行的运作更有效率、准确且扩充性，从而更易于管理大量生物样本。自动化在维护样本完整性方面发挥关键作用，它能够简化流程、减少人为错误并提高样本处理的可靠性。

此外，数位化工具改善了不同实验室和地区之间样本的追踪和管理，并促进了全球生物库网路之间更有效的数据共用和协作。随着对高品质、有组织的生物样本的需求不断增长，这一趋势预计将继续影响生物银行产业，并支持个人化医疗、基因组学和药物发现的进步。

本报告研究了全球生物银行市场，并总结了主要趋势、市场影响因素分析、法律制度、技术和专利分析、市场规模趋势和预测、各个细分市场、地区/主要国家的详细分析、竞争格局和主要企业的概况。

关键策略和发展
- M&A
- 协同活动
- 业务扩展和资金筹措
- 产品发布和核准
- 其他活动
公司简介
- Becton, Dickinson and Company
- QIAGEN NV
- Merck KGaA
- Thermo Fisher Scientific Inc.
- PHC Holdings Corporation
- Cryoport, Inc.
- Azenta, Inc.
- Avantor, Inc.
- Tecan Trading AG
- Greiner AG
- Bay Biosciences LLC
- Shanghai Zhangjiang Biobank
- US Biolab Corporation, Inc.
- Cureline
- Brooks Life Sciences

第11章调查方法

简介目录图表

Global Biobanking Market, Analysis and Forecast: 2025-2035

Biobanking refers to the process of collecting, storing, and managing biological samples (such as blood, tissue, DNA, RNA, and other bodily fluids) for research and medical purposes. These samples are preserved and catalogued in biorepositories or biobanks, where they are stored under controlled conditions to maintain their integrity for long-term use. Biobanks are invaluable resources for scientific research, particularly in fields like genomics, cancer research, drug development, and epidemiology.

Researchers use biobanks to investigate the genetic and environmental factors that contribute to diseases, understand disease mechanisms, and develop personalized treatments. Biobanks are also used for testing the efficacy of new medications, understanding population health trends, and advancing medical knowledge. With the growing focus on precision medicine, biobanks are becoming increasingly important as they provide high-quality biological samples that are essential for creating tailored healthcare solutions based on individual genetic profiles.

One of the key drivers of the biobanking market is the increasing demand for personalized medicine. As advancements in genomics and biotechnology continue to progress, there is a growing focus on tailoring medical treatments to individual patients based on their genetic makeup. Biobanks play a critical role in this area by storing diverse biological samples that can be used to understand genetic variations and their implications on health and disease. These samples help researchers develop targeted therapies and treatments that are more effective and less harmful to patients.

The rise in chronic diseases, such as cancer, diabetes, and cardiovascular conditions, further drives the need for biobanks. By providing a repository of biological materials, biobanks enable researchers to identify disease biomarkers, understand disease mechanisms, and develop new diagnostic and therapeutic methods. As personalized medicine becomes a central pillar of modern healthcare, the demand for biobanks and high-quality biological samples is expected to continue to grow.

Despite the growth of the biobanking market, several challenges persist. One of the primary challenges is the ethical and legal concerns associated with the collection, storage, and use of biological samples. Issues surrounding informed consent, privacy, and confidentiality of donor information remain a significant challenge. Ensuring that individuals provide informed consent for the use of their biological samples in research and that their privacy is protected is crucial, especially when dealing with sensitive genetic data.

Furthermore, the lack of uniform regulations and standardization in biobanking practices across different regions and institutions can lead to discrepancies in data quality, sample handling, and storage methods. This lack of standardization complicates data sharing and collaboration among research institutions, which can limit the global utility of biobank resources.

Lastly, there are financial, and infrastructure challenges related to maintaining biobanks, as they require significant investment in both the physical infrastructure (such as storage facilities) and technology to manage vast amounts of data and biological samples over extended periods.

The global Biobanking market is highly competitive, with major players such as Becton, Dickinson and Company, QIAGEN N.V., Merck KGaA, Thermo Fisher Scientific Inc., PHC Holdings Corporation, Cryoport, Inc., Azenta, Inc., Avantor, Inc., Tecan Trading AG, Greiner AG, Bay Biosciences LLC, Shanghai Zhangjiang Biobank, US Biolab Corporation, Inc., Cureline, and Brooks Life Sciences leading the way. These companies are continuously innovating and expanding their product portfolios to cater to the growing demand for biological sample storage, processing, and management in research, personalized medicine, and drug development.

The competition in the market is driven by advancements in technology, improvements in storage capabilities, and the increasing need for high-quality biological samples for clinical trials, genomic research, and disease study. With significant investments in infrastructure, digitalization, and regulatory compliance, these key players are well-positioned to shape the future of the biobanking market.

Biobanking Market Segmentation:

Segmentation 1: by Product and Service

Equipment
- Storage Equipment
- Sample Analysis Equipment
- Sample Processing Equipment
- Sample Transport Equipment
Consumables
- Storage Consumables
- Analysis Consumables
- Processing Consumables
- Collection Consumables
Services
- Storage Services
- Processing Services
- Transport Services
- Supply Services
Software

Segmentation 2: by Storage Type

Manual Storage
Automated Storage

Segmentation 3: by Sample Type

Blood Products
Human Tissues
Cell Lines
Nucleic Acids
Biological Fluids
Human Waste Products

Segmentation 4: by Ownership

Universities
National/Regional Agencies
Non-Profit Organizations
Private Organizations

Segmentation 5: by Biobank Type

Physical/Real Biobanks
Tissue Biobanks
Population-Based Biobanks
Genetic (DNA/RNA)
Disease-Based Biobanks
Virtual Biobanks

Segmentation 6: by Application

Regenerative Medicine
Life Science Research
Clinical Research

Segmentation 7: by End User

Pharmaceutical & Biotechnology Companies and Cros
Academic And Research Institutes
Hospitals

Segmentation 8: by Region

North America
Europe
Asia-Pacific
Rest of the World

One of the most significant emerging trends in the global biobanking market is the integration of digital technologies and automation. This trend involves the adoption of advanced data management systems, AI-driven platforms, and automation in sample collection, storage, and analysis. These technologies improve the efficiency, accuracy, and scalability of biobanking operations, making it easier to manage large volumes of biological samples. Automation helps streamline processes, reduces human error, and enhances the reliability of sample handling, which is crucial for maintaining sample integrity.

Moreover, digital tools enable better tracking and management of samples across different research facilities and regions, promoting more efficient data sharing and collaboration between global biobank networks. With the growing demand for high-quality and well-organized biological samples, this trend is expected to continue to shape the biobanking industry, supporting advancements in personalized medicine, genomics, and drug development.

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Global Biobanking Market: Industry Outlook

1.1 Introduction
1.2 Market Trends
1.3 Regulatory Framework
1.4 Case Studies
1.5 Product Benchmarking
1.6 Market Dynamics
- 1.6.1 Impact Analysis
- 1.6.2 Market Drivers
- 1.6.3 Market Challenges
- 1.6.4 Market Opportunities

2. Global Biobanking Market (by Product and Service), ($Billion), 2024-2035

2.1 Equipment
- 2.1.1 Storage Equipment
- 2.1.2 Sample Analysis Equipment
- 2.1.3 Sample Processing Equipment
- 2.1.4 Sample Transport Equipment
2.2 Consumables
- 2.2.1 Storage Consumables
- 2.2.2 Analysis Consumables
- 2.2.3 Processing Consumables
- 2.2.4 Collection Consumables
2.3 Services
- 2.3.1 Storage Services
- 2.3.2 Processing Services
- 2.3.3 Transport Services
- 2.3.4 Supply Services
2.4 Software

3. Global Biobanking Market (by Storage Type), ($Billion), 2024-2035

3.1 Manual Storage
3.2 Automated Storage

4. Global Biobanking Market (by Sample Type), ($Billion), 2024-2035

4.1 Blood Products
4.2 Human Tissues
4.3 Cell Lines
4.4 Nucleic Acids
4.5 Biological Fluids
4.6 Human Waste Products

5. Global Biobanking Market (by Ownership), ($Billion), 2024-2035

5.1 Universities
5.2 National/Regional Agencies
5.3 Non-Profit Organizations
5.4 Private Organizations

6. Global Biobanking Market (by Biobank Type), ($Billion), 2024-2035

6.1 Physical/Real Biobanks
6.2 Tissue Biobanks
6.3 Population-Based Biobanks
6.4 Genetic (DNA/RNA)
6.5 Disease-Based Biobanks
6.6 Virtual Biobanks

7. Global Biobanking Market (by Application), ($Billion), 2024-2035

7.1 Regenerative Medicine
7.2 Life Science Research
7.3 Clinical Research

8. Global Biobanking Market (by End User), ($Billion), 2024-2035

8.1 Pharmaceutical & Biotechnology Companies and Cros
8.2 Academic And Research Institutes
8.3 Hospitals

9. Global Biobanking Market (by Region), ($Billion), 2024-2035

9.1 North America
- 9.1.1 Key Findings
- 9.1.2 Market Dynamics
- 9.1.3 Market Sizing and Forecast
  - 9.1.3.1 North America Biobanking Market, by Country
    - 9.1.3.1.1 U.S.
    - 9.1.3.1.2 Canada
9.2 Europe
- 9.2.1 Key Findings
- 9.2.2 Market Dynamics
- 9.2.3 Market Sizing and Forecast
  - 9.2.3.1 Europe Biobanking Market, by Country
    - 9.2.3.1.1 Germany
    - 9.2.3.1.2 U.K.
    - 9.2.3.1.3 France
    - 9.2.3.1.4 Italy
    - 9.2.3.1.5 Spain
    - 9.2.3.1.6 Rest of the Europe
9.3 Asia Pacific
- 9.3.1 Key Findings
- 9.3.2 Market Dynamics
- 9.3.3 Market Sizing and Forecast
  - 9.3.3.1 Asia Pacific Biobanking Market, by Country
    - 9.3.3.1.1 China
    - 9.3.3.1.2 Japan
    - 9.3.3.1.3 India
    - 9.3.3.1.4 Australia
    - 9.3.3.1.5 Rest of Asia Pacific
9.4 Rest of the World
- 9.4.1 Key Findings
- 9.4.2 Market Dynamics
- 9.4.3 Market Sizing and Forecast

10. Global Biobanking Market: Competitive Landscape and Company Profiles

10.1 Key Strategies and Development
- 10.1.1 Mergers and Acquisitions
- 10.1.2 Synergistic Activities
- 10.1.3 Business Expansions and Funding
- 10.1.4 Product Launches and Approvals
- 10.1.5 Other Activities
10.2 Company Profiles
- 10.2.1 Becton, Dickinson and Company
  - 10.2.1.1 Overview
  - 10.2.1.2 Top Products / Product Portfolio
  - 10.2.1.3 Top Competitors
  - 10.2.1.4 Target Customers/End-Users
  - 10.2.1.5 Key Personnel
  - 10.2.1.6 Analyst View
- 10.2.2 QIAGEN N.V.
  - 10.2.2.1 Overview
  - 10.2.2.2 Top Products / Product Portfolio
  - 10.2.2.3 Top Competitors
  - 10.2.2.4 Target Customers/End-Users
  - 10.2.2.5 Key Personnel
  - 10.2.2.6 Analyst View
- 10.2.3 Merck KGaA
  - 10.2.3.1 Overview
  - 10.2.3.2 Top Products / Product Portfolio
  - 10.2.3.3 Top Competitors
  - 10.2.3.4 Target Customers/End-Users
  - 10.2.3.5 Key Personnel
  - 10.2.3.6 Analyst View
- 10.2.4 Thermo Fisher Scientific Inc.
  - 10.2.4.1 Overview
  - 10.2.4.2 Top Products / Product Portfolio
  - 10.2.4.3 Top Competitors
  - 10.2.4.4 Target Customers/End-Users
  - 10.2.4.5 Key Personnel
  - 10.2.4.6 Analyst View
- 10.2.5 PHC Holdings Corporation
  - 10.2.5.1 Overview
  - 10.2.5.2 Top Products / Product Portfolio
  - 10.2.5.3 Top Competitors
  - 10.2.5.4 Target Customers/End-Users
  - 10.2.5.5 Key Personnel
  - 10.2.5.6 Analyst View
- 10.2.6 Cryoport, Inc.
  - 10.2.6.1 Overview
  - 10.2.6.2 Top Products / Product Portfolio
  - 10.2.6.3 Top Competitors
  - 10.2.6.4 Target Customers/End-Users
  - 10.2.6.5 Key Personnel
  - 10.2.6.6 Analyst View
- 10.2.7 Azenta, Inc.
  - 10.2.7.1 Overview
  - 10.2.7.2 Top Products / Product Portfolio
  - 10.2.7.3 Top Competitors
  - 10.2.7.4 Target Customers/End-Users
  - 10.2.7.5 Key Personnel
  - 10.2.7.6 Analyst View
- 10.2.8 Avantor, Inc.
  - 10.2.8.1 Overview
  - 10.2.8.2 Top Products / Product Portfolio
  - 10.2.8.3 Top Competitors
  - 10.2.8.4 Target Customers/End-Users
  - 10.2.8.5 Key Personnel
  - 10.2.8.6 Analyst View
- 10.2.9 Tecan Trading AG
  - 10.2.9.1 Overview
  - 10.2.9.2 Top Products / Product Portfolio
  - 10.2.9.3 Top Competitors
  - 10.2.9.4 Target Customers/End-Users
  - 10.2.9.5 Key Personnel
  - 10.2.9.6 Analyst View
- 10.2.10 Greiner AG
  - 10.2.10.1 Overview
  - 10.2.10.2 Top Products / Product Portfolio
  - 10.2.10.3 Top Competitors
  - 10.2.10.4 Target Customers/End-Users
  - 10.2.10.5 Key Personnel
  - 10.2.10.6 Analyst View
- 10.2.11 Bay Biosciences LLC
  - 10.2.11.1 Overview
  - 10.2.11.2 Top Products / Product Portfolio
  - 10.2.11.3 Top Competitors
  - 10.2.11.4 Target Customers/End-Users
  - 10.2.11.5 Key Personnel
  - 10.2.11.6 Analyst View
- 10.2.12 Shanghai Zhangjiang Biobank
  - 10.2.12.1 Overview
  - 10.2.12.2 Top Products / Product Portfolio
  - 10.2.12.3 Top Competitors
  - 10.2.12.4 Target Customers/End-Users
  - 10.2.12.5 Key Personnel
  - 10.2.12.6 Analyst View
- 10.2.13 US Biolab Corporation, Inc.
  - 10.2.13.1 Overview
  - 10.2.13.2 Top Products / Product Portfolio
  - 10.2.13.3 Top Competitors
  - 10.2.13.4 Target Customers/End-Users
  - 10.2.13.5 Key Personnel
  - 10.2.13.6 Analyst View
- 10.2.14 Cureline
  - 10.2.14.1 Overview
  - 10.2.14.2 Top Products / Product Portfolio
  - 10.2.14.3 Top Competitors
  - 10.2.14.4 Target Customers/End-Users
  - 10.2.14.5 Key Personnel
  - 10.2.14.6 Analyst View
- 10.2.15 Brooks Life Sciences
  - 10.2.15.1 Overview
  - 10.2.15.2 Top Products / Product Portfolio
  - 10.2.15.3 Top Competitors
  - 10.2.15.4 Target Customers/End-Users
  - 10.2.15.5 Key Personnel
  - 10.2.15.6 Analyst View

11. Research Methodology

简介目录图表

List of Figures

Figure: Global Biobanking Market (by Product and Service), $Billion, 2024 and 2035
Figure: Global Biobanking Market (by Storage Type), $Billion, 2024 and 2035
Figure: Global Biobanking Market (by Sample Type), $Billion, 2024 and 2035
Figure: Global Biobanking Market (by Ownership), $Billion, 2024 and 2035
Figure: Global Biobanking Market (by Biobank Type), $Billion, 2024 and 2035
Figure: Global Biobanking Market (by Application), $Billion, 2024 and 2035
Figure: Global Biobanking Market (by End User), $Billion, 2024 and 2035
Figure: Global Biobanking Market (by Region), $Billion, 2024 and 2035
Figure: Global Biobanking Market Key Trends, Analysis

List of Tables

Table: Global Biobanking Market Dynamics, Impact Analysis
Table: Global Biobanking Market (by Region), $Billion, 2024-2035

02-2729-4219

+886-2-2729-4219

License/价格

生物银行市场 - 全球和区域分析：按产品和服务、储存类型、样本类型、所有者、生物银行类型、应用、国家和地区进行分析和预测（2025-2035 年）

Biobanking Market - A Global and Regional Analysis: Focus on Product and Service, Storage Type, Sample Type, Ownership, Biobank Type, Application, Country, and Region - Analysis and Forecast, 2025-2035

目录

执行摘要

第一章全球生物银行市场：产业展望

第二章：全球生物银行市场（按产品和服务）

3. 全球生物银行市场按储存类型划分

4. 全球生物银行市场（依样本类型）

5. 全球生物银行市场（依所有权划分）

6. 全球生物银行市场（依生物银行类型）

7. 全球生物银行市场（按应用）

8. 全球生物银行市场（依最终用户）

9. 全球生物银行市场（按地区）

第 10 章：全球生物银行市场：竞争格局与公司概况